PAR 2.56% 20.0¢ paradigm biopharmaceuticals limited..

General OA media and info, page-528

  1. 832 Posts.
    lightbulb Created with Sketch. 331

    Aat least got a mention which means we are on the radar....
    These numbers are old however "Symptomatic Knee Osteoarthritis population = 47,874,567 (2021)"
    Say we treat 5% of the population to be conservative = 2,393,728
    Treatment $3500 AUD x 2,393,728 = $8,378,049,225
    Lets say royalty is 20% - 20% x $8,378,049,225 = $1,675,609,845
    This is a reasonably conservtive number ..
    if we can prove DMOAD and/or become Primary treatment that will increase both the treatment price and population.
    SO my question is why would they not go and do a deal with J&J for say 20% royalty (for PAR) and J&J gives us a $50m upfront (to complete phase 3) ... Problem solved. No Dilution, we get a partner and we can all call the Merc dealer...


    The Pool

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.